Stockscreener 앱 받기
8.36
0.97%
0.08
Regenxbio Inc 주식(RGNX)의 최신 뉴스
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit – Company Announcement - Financial Times
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class - PharmiWeb.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - marketscreener.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
REGENXBIO, Inc. Stockholders Should Contact Robbins LLP for Information About Leading the RGNX Class Action - The Joplin Globe
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP - Finviz
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
RGNX DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Regenxbio reports Duchenne gene therapy progress as stock slides on mixed signals - MSN
Ideas Watch: What is the earnings history of REGENXBIO Inc2026 Closing Moves & Expert Curated Trade Ideas - baoquankhu1.vn
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 earnings call transcript - MSN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - ChartMill
Regenxbio says its gene therapy for muscle disorder showed no evidence of liver injury in study - MSN
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against REGENXBIO Inc. (RGNX), Franklin BSP Realty Trust, Inc. (FBRT), and Aquestive Therapeutics, Inc. (AQST) Announced by Holzer & Holzer, LLC - marketscreener.com
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm - PR Newswire
Invenomic Capital Management LP Makes New $4.12 Million Investment in REGENXBIO Inc. $RGNX - MarketBeat
RGNX's "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com Nigeria
Denali’s Hunter Syndrome Candidate in the Spotlight After REGENXBIO Rejection - BioSpace
Regenxbio reports positive interim data for Duchenne gene therapy By Investing.com - Investing.com Nigeria
RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 (2026-03-15) - Seeking Alpha
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - bhpioneer.com
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. - GlobeNewswire
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
Integral Health Asset Management LLC Acquires 400,000 Shares of REGENXBIO Inc. $RGNX - MarketBeat
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - ChartMill
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
RGNX Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Positive interim data for Regenxbio’s gene therapy in DMD - The Pharmaletter
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com Nigeria
Insider Sell Alert: Steve Pakola Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
17:55 ETRGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - Longbridge
REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 5,124 Shares - MarketBeat
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock - Investing.com Nigeria
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock By Investing.com - Investing.com India
REGENXBIO (RGNX) CMO sells 5,124 shares under 10b5-1 plan - Stock Titan
MDA: Vinay away, AA in play for Regenxbio gene therapy? - BioWorld MedTech
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific ConferenceSlideshow - Seeking Alpha
RGNX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST - Stock Titan
Stifel reiterates Regenxbio stock rating on Duchenne trial data - Investing.com UK
Stifel reiterates Regenxbio stock rating on Duchenne trial data By Investing.com - Investing.com Canada
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, - GlobeNewswire
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study - Stocktwits
Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals - Benzinga
REGENXBIO (RGNX) Reports Promising Interim Results for Duchenne Gene Therapy - GuruFocus
1.20%
0.06%
자본화:
|
볼륨(24시간):